There is no FDA-approved generic version of Wegovy as of 2026. The scientific (nonproprietary) name for Wegovy’s active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk. Semaglutide remains under patent and regulatory exclusivity in the United States, which means only brand-name semaglutide products such as Wegovy, Ozempic, and Rybelsus are legally available through traditional pharmacies.
What “Generic” Actually Means
In pharmaceutical terms, a generic drug is an FDA-approved version of a brand-name drug containing the same active ingredient, strength, dosage form, and route of administration. To reach the market, a generic manufacturer must prove bioequivalence and receive approval through an Abbreviated New Drug Application (ANDA). For complex biologic or peptide drugs, a similar approval pathway (biosimilar) applies. No manufacturer has received FDA approval for a semaglutide generic or biosimilar to date.
The scientific name, semaglutide, is sometimes colloquially called the “generic name,” but that usage refers to the active ingredient identifier, not a lower-cost copy of the drug. Understanding this distinction helps when navigating pharmacy and telehealth conversations about GLP-1 treatment options.
Why No Generic Exists Yet
Several factors delay generic competition for Wegovy.
- Active patents. Novo Nordisk holds multiple patents covering semaglutide and its formulations, with varying expiration dates extending into the late 2020s and beyond.
- Regulatory exclusivity. FDA-granted exclusivities overlap with patent protections and can delay generic approval.
- Manufacturing complexity. Semaglutide is a 31-amino-acid peptide produced through recombinant technology, which is harder to replicate than small-molecule drugs like metformin.
- Delivery system. Wegovy uses a proprietary prefilled pen; a generic would need an equivalent device or bridging data.
What About Compounded Semaglutide
During the FDA-declared shortage of semaglutide (2022 to 2024), licensed compounding pharmacies could legally prepare individualized semaglutide formulations for patients. These products were not generics and did not undergo FDA review for safety or effectiveness. After Novo Nordisk’s supply recovered and the shortage was resolved, the FDA tightened enforcement against compounded semaglutide, especially products sold through large online channels. According to the FDA, many compounded products have raised safety concerns, and regulators have advised caution.
Semaglutide Brands at a Glance
The same active ingredient appears in three different brands with distinct indications and doses.
| Brand | Active Ingredient | Indication | Dose | Route |
|---|---|---|---|---|
| Wegovy | Semaglutide | Chronic weight management; CV risk reduction in certain adults | 0.25 to 2.4 mg | Injection, weekly |
| Ozempic | Semaglutide | Type 2 diabetes; CV risk in type 2 diabetes | 0.25 to 2.0 mg | Injection, weekly |
| Rybelsus | Semaglutide | Type 2 diabetes | 3, 7, 14 mg | Oral, daily |
Wegovy cannot be substituted with Ozempic or Rybelsus by a pharmacist even though all three contain semaglutide, because each is FDA-approved for different indications and dose ranges. Only a prescriber can decide whether switching between products is appropriate for a given patient.
Cost and Access Without a Generic
Wegovy’s US list price is roughly $1,350 for a 28-day supply. Out-of-pocket costs depend on insurance coverage, which varies widely by employer plan, state Medicaid rules, and Medicare policy. Novo Nordisk offers a savings card that can reduce monthly cost for eligible commercially insured patients. Patient assistance programs may cover uninsured patients who meet income criteria. Cash pay through direct-to-consumer programs became available in 2024 at a reduced rate for certain doses. Our treatment hub covers comparative access strategies.
Risks of Seeking “Generic Wegovy” Online
Because demand for GLP-1 medications remains high, many websites advertise “generic Wegovy” or very low-cost semaglutide. These products are often either compounded semaglutide (now restricted), research-grade peptides not intended for human use, or outright counterfeits. Risks include contamination, inaccurate dosing, infection from nonsterile preparations, and no recourse if adverse events occur. Buying peptides from unlicensed sources is generally unsafe and, in some cases, illegal.
Looking Ahead
Semaglutide patent expiration is expected to begin in the late 2020s, with specific timing varying by country and patent. Even then, biosimilar or generic approval requires additional regulatory steps that can take several years. Analysts expect that when competition arrives, the first generic prices may still be substantially higher than traditional small-molecule generics because peptide manufacturing is expensive. Prices typically drop further as more competitors enter.
New competing drugs, such as tirzepatide (Mounjaro and Zepbound) and potential future oral GLP-1 candidates, also shape the pricing environment. Manufacturer price concessions and insurance negotiations may reduce Wegovy costs before any true generic arrives. For background on the broader drug class and how these drugs compare, see our explainer on A1C levels and typical treatment responses.
The Bottom Line
A Wegovy generic does not currently exist. Semaglutide, the active ingredient, is the scientific name sometimes mistaken for a generic version, but no FDA-approved copy is available. Compounded semaglutide is not a generic and is now more restricted. Until patents expire and a true generic or biosimilar is approved, the most reliable paths to affordable access are insurance coverage, manufacturer savings programs, and prescriber-guided therapy decisions.
Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or treatment.
